Silencing Inflammatory Activity by Injecting Nanocort in Patients at Risk for Atherosclerotic Disease

NCT01601106 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Atherosclerosis
Inflammation

Interventions

DRUG: liposomal prednisolone
DRUG: Placebo

Sponsor

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)